Aspire Biopharma Holdings, Inc. ASBP
8.32
(0.38)
(4.37%)
as of 25 Sep
- Market cap
- $12.2M
- P/E
- 0.2×
Follow ASBP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — |
P/Operating CF |
(0.28) | — | — | — | — |
P/B ratio |
0.00 | — | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | — |
EV/Operating CF |
(0.42) | — | — | — | — |
EV/FCF |
(0.42) | — | — | — | — |
Quick Ratio |
0.13 | 0.00 | 0.00 | 1.64 | 0.00 |
Current Ratio |
0.17 | 0.09 | 0.20 | 3.62 | 1.00 |
Net Debt/EBITDA |
(0.16) | (11.36) | 0.00 | 0.51 | (9.36) |
Debt/Assets |
212.66% | 9,297.84% | 0.00% | 0.00% | 81.38% |
Debt/Equity |
(0.44) | (8.93) | 0.00 | 0.00 | (477.20) |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.20 | 0.20 | (0.15) | (0.42) | 9.36 |
Capex/Depreciation |
0.00 | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 618.49% | 140.68% | (87.02%) | (67.22%) | 0.00% | |
| (3,353.09%) | (13.01%) | 2.79% | 2.22% | 0.00% | |
ROIC |
0.00% | (6.19%) | 0.00% | 0.00% | (6.69%) |
Return on Tangible Assets |
389.79% | 85.05% | (1,385.94%) | 420.42% | 5,100.00% |
Average Days of Receivables |
0.00 | — | — | — | — |
Research and Development Expense of Revenue |
14,901.61% | 0.00% | — | — | — |
Selling, General and Administrative Expense of Revenue |
297,214.52% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
227,924.19% | — | — | — | — |
Graham Net Nets |
(24.25) | — | — | — | — |
Graham Number |
1,193.46 | — | — | — | — |
Earnings Yield |
(9,363.89%) | — | — | — | — |
Free Cash Flow Yield |
(1,872.45%) | — | — | — | — |
Revenue per Share |
0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(98.87) | (11.53) | (283.96) | (234.80) | (45.88) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(98.87) | (11.53) | (283.96) | (234.80) | (45.88) |
Cash per Share |
20.16 | 0.16 | 0.00 | 82.88 | 0.00 |
Shareholders Equity per Share |
(128.04) | (66.96) | (140.04) | (1,656.32) | (0.10) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(128.04) | (66.96) | (140.04) | (1,656.32) | (0.10) |
Free Cash Flow |
(4.92) | (0.27) | (0.65) | (1.41) | (0.24) |
Working Capital |
(6.28) | (1.54) | (0.32) | 0.79 | 0.00 |
Net Current Asset Value |
(6.38) | (1.54) | (20.22) | (309.02) | 0.00 |
EV/EBIT |
0.00 | — | — | — | — |
Capex to Sales |
0.00 | — | — | — | — |
Net Profit Margin |
(394,853.23%) | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | — | — | — | — |
| Other line items | |||||
Depreciation/Fixed assets |
0.00 | — | — | — | — |
Cash ROIC |
190.69% | (2.17%) | 202.76% | 14.92% | (100.21%) |
Accounts Receivable Turnover |
0.00 | — | — | — | — |
Accounts Payable Turnover |
0.01 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | — | — | — | — |
Average Days of Payables |
58,770.79 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
14,669.52 | — | — | — | — |
Average Payables |
0.66 | 0.23 | 0.17 | 0.09 | — |
Average Assets |
0.73 | 10.07 | 160.08 | 150.24 | — |
Average Common Equity |
(3.96) | (0.93) | (5.13) | (4.97) | — |
Columns are period end dates